Screener Summaries Updates Institutions Sign In More Updates › Other Events › OTLK Other Events · Jun 26, 2026
Outlook Therapeutics, Inc. regained compliance with the Nasdaq Capital Market minimum bid price requirement of $1.00… OTLK Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. regained compliance with the Nasdaq Capital Market minimum bid price requirement of $1.00 per share after its common stock closing bid price remained at or above that threshold for ten consecutive business days from June 11, 2026, to June 25, 2026. The company is no longer under delisting notice. Outlook Therapeutics, Inc. is a biotechnology company focused on developing and commercializing ophthalmic therapies.
More from Outlook Therapeutics, Inc. Nasdaq notifies Outlook Therapeutics of non-compliance with $1.00 minimum bid price requirement Sep 30, 2026 Outlook Therapeutics announced that CFO Lawrence A. Kenyon mutually agreed to cease serving as Chief Financial… Aug 27, 2026 On August 12, 2026, Outlook Therapeutics entered into an underwriting agreement for a public offering of 55,555,556… Aug 14, 2026 Outlook Therapeutics reported preliminary cash and cash equivalents of approximately $11.2 million as of June 30, 2026 Aug 12, 2026 On July 21, 2026, Outlook Therapeutics, Inc. announced stock option grants to CEO Robert C. Jahr (100,000 options) and… Jul 23, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
